EMBL Ventures
Venture capitalHeidelberg · Seed–Late Stage
Investment thesis
EMBL Ventures invests in life science companies throughout Europe, aiming to build businesses with significant commercial potential in areas such as new therapeutic treatment modalities and pharmaceuticals, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. The firm draws on a strong scientific and life science industry network, an established investment track record, and experience building companies, structuring collaboration and licensing agreements, and executing M&A and IPOs. Portfolio companies receive hands-on support, access to the firm's network, and unique access to the EMBL, which the firm views as a source of added value.
Source: firm website, verified Aug 3, 2026.
What they invest in
from 2 of 10 portfolio companiesBiotech ×2Healthtech ×2Medical Devices ×1
HQs:Germany×1United States×1
Investments · 10 tracked
founders shown can be your intro pathTopas Therapeutics develops liver-directed tolerance therapies aimed at inducing immune tolerance to treat autoimmune and immune-mediated diseases.
BiotechHealthtechMedical Devices
Hugo Fry(Chief Executive Officer)Christian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)
Co-investorsBoehringer Ingelheim Venture FundGimvBioMedPartnersEpidarex Capital
Antibiotic developer, maker of cefepime/enmetazobactam (EXBLIFEP).
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Crestwood, US
Co-investorsEpidarex CapitalvenBio Partners
Anti-infective monoclonal antibody company.
Crescendo Biologics develops T cell enhancing therapeutics for immuno-oncology, based on its Humabody platform, with clinical candidates including the bispecific CB307 and immune cell engager CB699.
BiotechHealthtech
Co-investorsAndera PartnersAstellas Venture Management LLCFuture Planet CapitalQuan CapitalSofinnova Partners
Light-sheet microscopy company acquired by Bruker.
Oncolytic virus therapeutics company acquired by Boehringer Ingelheim.
Exits · 2
IPOs and acquisitions across the tracked portfolioLuxendoacq. by BrukerViraTherapeuticsacq. by Boehringer Ingelheim
Frequently asked questions
- How many investments has EMBL Ventures made?
- EMBL Ventures has 10 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does EMBL Ventures invest at?
- EMBL Ventures invests at the Seed, Series A, Late Stage stages.
- What is EMBL Ventures's typical check size?
- EMBL Ventures typically writes checks of $108K – $5.4M.
- What sectors does EMBL Ventures focus on?
- EMBL Ventures focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is EMBL Ventures located?
- EMBL Ventures is headquartered in Heidelberg, DE.
- Who does EMBL Ventures co-invest with?
- EMBL Ventures most often shares deals with Epidarex Capital, BioMedPartners, Future Planet Capital, among 10 tracked co-investors.
Images
Similar investors
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.